CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 153 enrolled
Drug / intervention
Dutasteride 0.5mg oral tabletsdrug
Likely dose
Dutasteride 0.5mg oral tabletsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00441116
NCT00441116Phase 3Completed
CompareCT.gov

An Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of Dutasteride 0.5mg Once Daily for 6 Months in the Treatment of Male Subjects With Androgenetic Alopecia (Norwood-Hamilton Classification Type IIIv, IV and V)

GlaxoSmithKline·interventional·Posted Feb 28, 2007·Updated Aug 16, 2018

In Brief

A Phase 3 clinical trial evaluating Dutasteride 0.5mg oral tablets for Alopecia. Completed, enrolled 153 participants.

Detailed Summary

The aim of this Phase III study is to compare the efficacy, safety and tolerability of dutasteride (0.5mg) with placebo for 6 months, in Korean male subjects with androgenetic alopecia in the vertex region, types IIIv, IV and V according to the modified Norwood-Hamilton Classification.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlopecia
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 28, 2007
Enrollment StartDec 15, 2006
Primary CompletionJan 21, 2008
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 19.3 years ago

Interventions

Dutasteride 0.5mg oral tabletsdrug

Dutasteride